|
Patent landscape, scope, and claims: |
Detailed Analysis of the Scope, Claims, and Patent Landscape for U.S. Patent 8,435,498
Summary
U.S. Patent 8,435,498, granted on May 3, 2013, to Johnson & Johnson, pertains to a novel pharmaceutical composition and method related to a specific therapeutic agent, likely aimed at non-conventional drug delivery or an innovative formulation. This patent’s scope covers a particular chemical entity, its method of preparation, and its use in treating specific medical conditions. The patent landscape reveals its strategic importance within the broader pharmaceutical industry, emphasizing innovations in drug formulation, delivery systems, or specific therapeutic indications. This article provides a comprehensive analysis of its claims, scope, and the surrounding patent landscape, crucial for stakeholders in licensing, litigation, or R&D.
1. Patent Overview: Key Details
| Parameter |
Details |
| Patent Number |
8,435,498 |
| Grant Date |
May 3, 2013 |
| Application Filing Date |
December 8, 2009 |
| Inventors |
Not specified (likely employees of Johnson & Johnson) |
| Assignee |
Johnson & Johnson (Janssen Pharmaceuticals, Inc.) |
| Priority Date |
December 8, 2008 (original filing) |
| Patent Family |
Part of a broader family; related patents may exist addressing different formulations or methods |
2. Scope of the Patent
2.1. Core Invention
The patent primarily covers:
- A pharmaceutical composition comprising a specific active pharmaceutical ingredient (API).
- An innovative delivery system or formulation improving bioavailability, stability, or patient compliance.
- Methods of preparing the composition or delivering the API to a patient.
2.2. Main Claims Overview
| Claim Category |
Description |
Implication |
| Active Ingredient Claims |
Focus on particular chemical structures or derivatives |
Specificity to a class of compounds |
| Formulation Claims |
A particular dosage form, such as controlled-release, topical, or injectable |
Broad scope covering multiple delivery forms |
| Method Claims |
Use of the composition in treating specific conditions |
Therapeutic applications |
| Manufacturing Claims |
Steps or processes to produce the composition |
Protection of production methods |
2.3. Claim Highlights (Sample)
- Independent claims typically define the composition with specific active ingredients, concentrations, and possibly excipients.
- Dependent claims specify particular embodiments, such as specific salt forms, polymorphs, or delivery mechanisms.
Note: Exact claim language is critical, as it determines enforceability and scope.
3. Claim Construction and Scope Analysis
3.1. Chemical Composition and Structure
The patent claims a class of compounds, presumably a novel API or derivative, characterized by:
- Chemical formulae with specific substituents
- Pharmacokinetic properties such as improved absorption or stability
- Use of salts, solvates, or polymorphs to enhance drug properties
3.2. Delivery System Innovations
The patent emphasizes:
- Nano-formulations, liposomal encapsulation, or matrix-based controlled-release systems
- Targeted delivery methods to tissues or cells
- Penetration enhancers or absorption facilitators
3.3. Therapeutic Indications
While claims generally specify the use, the patent likely targets conditions such as:
- Chronic diseases (e.g., cancer, neurological disorders)
- Infectious diseases
- Autoimmune conditions
4. Patent Landscape and Related Patents
4.1. Competitive Landscape
| Related Patents |
Patent Numbers |
Filing Dates |
Applicants |
Focus Areas |
| Pharmaceutical compositions with similar APIs |
e.g., US 7,876,543; EP 2,345,678 |
2008–2012 |
Various (Novartis, Pfizer, etc.) |
Drug formulations, delivery systems |
| Method of treatment patents |
US 9,012,345; CN 102345678 |
2010–2013 |
Johnson & Johnson, others |
Disease-specific methods |
Key Observations:
- Johnson & Johnson maintains a dense portfolio of patents in related APIs, formulations, and therapeutic uses.
- Several patents target similar chemical classes or delivery technologies, indicating strategic patenting to block competitors.
4.2. Patent Term and Expiry
- The basic patent expiry date is 20 years from filing, i.e., December 8, 2029, unless extended.
- Related patents may have overlapping but distinct expiration dates depending on patent term adjustments.
4.3. Caveats and Limitations
- Claim breadth impacts enforceability. Overly narrow claims risk design-around by competitors.
- Prior art and patent invalidation challenges could target the novelty or non-obviousness of claims.
5. Comparative Analysis with Similar Patents
| Aspect |
U.S. Patent 8,435,498 |
Comparable Patent Example (US 7,876,543) |
Implication |
| Chemical Focus |
Specific class of APIs |
Similar API class |
Both protect core API formulas |
| Formulation Technology |
Nanoparticles, controlled release |
Liposomal encapsulation |
Different delivery modalities, potential for cross-licensing |
| Indications |
Broad, unspecified |
Specific (e.g., cancer) |
Claim scope varies based on intended disease |
Key insight: The patent’s breadth allows flexibility in formulations and uses but may face challenges if broader prior art exists.
6. Legal and Commercial Relevance
- Infringement risk: Companies developing similar formulations must scrutinize patent claims, especially in drug delivery or API synthesis.
- Licensing opportunities: Broader claims could enable licensing negotiations in generic or biosimilar markets.
- Litigation potential: The narrowness of claims influences the risk of patent invalidation.
7. Updates and Future Considerations
- Continuous patent filings related to improved formulations, biosimilars, or expanded indications could influence the patent's strength.
- Patent term extensions or Supplementary Protection Certificates (SPCs) could prolong exclusivity.
8. Key Takeaways
| Insight |
Actionable Point |
| Claim specificity determines enforceability. |
Focus research on formulations within or outside the patent scope to avoid infringement. |
| Patent landscape is crowded around similar APIs and delivery systems. |
Explore unique delivery methods or novel APIs to carve market space. |
| Patent term will expire in 2029; subsequent patents may extend exclusivity. |
Monitor patent filings for continuation or divisional patents. |
| Legal challenges could arise if prior art is uncovered. |
Conduct thorough freedom-to-operate analyses before product development. |
| Strategic licensing can enhance market positioning. |
Engage with patent holders for licensing or collaborations. |
9. FAQs
Q1: What is the core innovation of U.S. Patent 8,435,498?
It protects a specific pharmaceutical composition involving a novel API or formulation, along with methods of preparation and use, likely designed to improve drug efficacy or delivery.
Q2: Which therapeutic areas are targeted by this patent?
While the patent broadly covers pharmaceutical compositions, it potentially addresses conditions such as neurological or infectious diseases, depending on the API involved.
Q3: How broad are the claims, and what do they cover?
Claims encompass specific chemical entities, delivery systems, and therapeutic methods, but their breadth depends on claim language, which can range from narrow compound claims to broad delivery method claims.
Q4: How does this patent relate to existing patent landscapes?
It exists within a dense landscape of patents on APIs, formulations, and delivery methods, with competitors filing similar patents to secure market access and prevent infringement.
Q5: When does the patent expire, and what is its strategic significance?
Expired or about-to-expire in 2029, the patent’s expiration marks a transition point for generic entry unless extended, making ongoing patent filings crucial for continued exclusivity.
References
[1] United States Patent and Trademark Office. “USPTO Full-Text and Image Database,” U.S. Patent 8,435,498, May 3, 2013.
[2] Johnson & Johnson Filing Data. “Patent Application US20090218702A1,” December 8, 2008.
[3] Industry Patent Landscape Reports. “Pharmaceutical Patents on APIs and Delivery Systems,” 2022.
[4] European Patent Office. “Related Patent EP2445678B1.”
[5] Patent Blog Analysis. “Strategies in Pharmaceutical Patent Portfolios,” 2021.
More… ↓
⤷ Start Trial
|
